Servier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billion

Servier has agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, adding late-stage investigational therapy sevasemten and strengthening its position in rare neuromuscular diseases. The transaction includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments.

The deal has received approval from both companies’ governance bodies and is expected to close in the third quarter of 2026, subject to regulatory clearances and customary closing conditions.

Sevasemten: A Late-Stage Neuromuscular Asset

The acquisition brings sevasemten, an orally administered, first-in-class fast skeletal myosin inhibitor that targets the underlying muscle damage associated with muscular dystrophies. The therapy reduces excessive muscle contraction forces that contribute to ongoing muscle injury, helping protect fragile muscle fibers from contraction-induced damage.

By preserving muscle integrity, sevasemten has the potential to slow functional decline in patients with progressive neuromuscular disorders.

The program is currently advancing through a pivotal clinical cohort in Becker muscular dystrophy (BMD) while continuing Phase 2 evaluation in Duchenne muscular dystrophy (DMD), making it a key late-stage asset in Servier’s expanding neurology portfolio.

Disease Context and Unmet Need

Both BMD and DMD are rare inherited neuromuscular disorders caused by mutations in the dystrophin gene, leading to progressive muscle degeneration and loss of function.

Becker muscular dystrophy is characterized by gradual muscle weakness and declining mobility. Despite its significant disease burden, no approved disease-modifying therapies are currently available for patients.

Duchenne muscular dystrophy is a more severe form of the disease that begins in early childhood. Patients typically lose the ability to walk during adolescence, and the condition is associated with a median life expectancy of approximately 30 years.

While recent therapeutic advances have improved care for some patients, substantial unmet medical need remains across both disorders.

Strategic Expansion in Rare Neurology

The acquisition marks an important step in Servier’s Servier 2030 strategy and reinforces the company’s ambition to build a focused portfolio in rare neurological diseases.

Olivier Laureau, President of Servier, said the transaction expands the company’s capabilities in neuromuscular disorders by adding specialized expertise and a promising late-stage development program. He noted that advancing treatments for patients living with debilitating rare neurological conditions remains a central priority for the organization.

Servier continues to invest across multiple high-unmet-need neurological indications, including refractory epilepsy, autism spectrum disorders, movement disorders, and neuromuscular diseases.

Outlook and Next Milestones

Edgewise CEO Kevin Koch said Servier’s global infrastructure and rare disease focus will accelerate sevasemten’s late-stage development. Following the expected Q3 2026 closing, Servier will take over clinical advancement and commercialization.

Near-term priorities include progress in the pivotal Becker muscular dystrophy program and continued Phase 2 evaluation in Duchenne muscular dystrophy, which will shape the therapy’s regulatory pathway and potential market entry.

Reference

Acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business